[Drug-induced diffuse infiltrative pneumopathies].
Drug-induced diffuse infiltrative pneumopathies (DIP) represent an important chapter of respiratory diseases. More than 350 drugs have been described to be potentially pneumo-toxic and the list is constantly increasing. As for other forms of DIP, also for drug-induced lung injury a multidisciplinary approach within pulmonologist, radiologist and pathologist is essential for the better diagnostic accuracy. In this review, clinical-radiological-pathological-therapeutic aspects of the drugs which are more likely to induce DIP in the clinical practice are described.
Scala
Raffaele
R
UO Pneumologia, UTSIR e Endoscopia Toracica, Ospedale S. Donato, AUSL 8 Arezzo. raffaele_scala@hotmail.com
Naldi
Mario
M
Ciccotosto
Cesario
C
Magnolfi
Annalisa
A
La Magra
Lidia Calogera
LC
Mariotti
Donatella
D
Coniglio
Giovanni
G
D000892:Anti-Infective Agents, Urinary / Q000009:adverse effects; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D003937:Diagnosis, Differential; D005493:Folic Acid Antagonists / Q000009:adverse effects; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis*; D011379:Prognosis; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000175:diagnosis
D000892:Anti-Infective Agents, Urinary; D000903:Antibiotics, Antineoplastic; D018906:Antineoplastic Agents, Alkylating; D018501:Antirheumatic Agents; D005493:Folic Acid Antagonists